Spotlight Interview: Andy Whiting – Nevrargenics Ltd
Nevrargenics Ltd is a UK-based neuroscience company specialising in the discovery and development of novel medicines for the treatment of neurodegenerative disease, such as Alzheimer’s, Parkinson’s, Multiple Sclerosis, Amyotrophic Lateral Sclerosis and other neurological and psychiatric diseases
Prof Andy Whiting is the inventor that Nevrargenics is founded upon, founder of the company, Director and CEO. The company went from spinout to independent spinout in June 2021 and is in the process of raising funds to drive the development of the company and the drug development programme, and is acquiring people.
What has the past 12 months taught you?
To set up a spinout through one university (such as with LightOx) is an interesting study in patience; to spinout from two (Durham and Aberdeen) is a total nightmare never to be repeated! COVID by comparison has been less of challenge, or at least for me personally.
What is your personal philosophy?
To be patient….very, very patient, although not a natural home for me! Being less flippant, I would say, my personal philosophy is not to be put off even when people say, “you can’t do this,” or that “its too difficult”, to prove them wrong. Problems are to be overcome.
What is your favourite part of your role?
Trying to realise the vision of what is probably THE biggest health challenge for the World, i.e. the growing unmet need of neurodegenerative diseases.
